Filament BioSolutions, a development-stage company focused on delivering therapeutics for nutritional deficiencies, continued progress in the development of its lead product FB-2710, an oral formulation of alanyl-glutamine, for the prevention of radiation-induced oral mucositis in head and neck cancer patients. The company is developing FB-2710 in collaboration with Ajinomoto Co., Inc., a global manufacturer of amino acids for the pharmaceutical and food industry. Oral mucositis is a debilita...